COMMUNIQUÉS West-GlobeNewswire

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

04/11/2024 - 22:05

RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

04/11/2024 - 22:05

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC Topline Phase 1 dose escalation data for FHD- [...]

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

04/11/2024 - 22:05

13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable efficacy results as [...]

Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024

04/11/2024 - 22:05

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for [...]

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

04/11/2024 - 22:05

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04/11/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]

FibroGen to Report Third Quarter 2024 Financial Results

04/11/2024 - 22:05

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference [...]

NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

04/11/2024 - 22:05

The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy The RNS System PAS evaluates safety and effectiveness of the [...]

Codexis to Participate in Upcoming Healthcare Conferences

04/11/2024 - 22:05

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will [...]

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

04/11/2024 - 22:15

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

04/11/2024 - 22:15

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric [...]

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/11/2024 - 22:15

WALTHAM, Mass and DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address [...]

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

04/11/2024 - 22:30

Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo [...]

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

04/11/2024 - 22:30

● Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ● Q3 Test volume up 26% year over year to record levels ● Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ● Q3 Volume, [...]

UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates

04/11/2024 - 22:30

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported [...]

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

04/11/2024 - 22:30

JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of [...]

Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités

04/11/2024 - 22:30

UCART22 et UCART20x22 : recrutement de patients en cours, un ensemble de données de la Phase 1 et la stratégie de développement seront présentées en 2025 Partenariat avec AstraZeneca dans le domaine des CAR T [...]

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

04/11/2024 - 22:30

UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025 AstraZeneca partnership: R&D activities are ongoing on three programs – one allogeneic CAR T [...]

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

04/11/2024 - 22:30

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief [...]